Assessment of Cannabidiolic Acid’s Neuroprotective Potential in a TDP-43 Transgenic Mouse Model of Amyotrophic Lateral Sclerosis

Cannabinoids originating from plants, such as Δ9-tetrahydrocannabinol (Δ9-THC), cannabinol, and formulations resembling Sativex, have demonstrated neuroprotective properties in various preclinical models of amyotrophic lateral sclerosis (ALS). Nevertheless, the therapeutic potential of lesser-known phytocannabinoids, including cannabidiolic acid (CBDA), has not been extensively investigated. The present investigation examined the neuroprotective capabilities of CBDA, alongside cannabidivarin, cannabidiol (CBD),…

Byneuroots.coDecember 9, 20250Comments

Science & Research

Peptides, NAD⁺, and MOTS-c: Evidence-Based Insights into Their Roles in Longevity as of 2025

In the domain of longevity research, peptides have garnered significant attention, yet only a subset demonstrates robust mechanistic support derived from empirical investigations. This review synthesizes validated findings from preclinical and clinical studies, while acknowledging constraints such as the paucity of comprehensive human data. BPC-157: Implications for Tissue Repair and Gastrointestinal Barrier Function Extensive preclinical…

Byneuroots.coDecember 3, 20250Comments

Epigenetics

A Unified Prime Editing Strategy for Mitigating Diverse Genetic Disorders

Advancements in genome editing have introduced a novel approach capable of addressing a substantial proportion of rare genetic conditions, potentially enhancing the scalability of therapeutic interventions for affected individuals. This innovative prime editing methodology targets nonsense mutations, which prematurely terminate protein synthesis and underlie approximately one-third of inherited diseases. In investigations led by David Liu…

Byneuroots.coDecember 2, 20250Comments

BNM Clinical Trials Epigenetics MND

Revolutionizing ALS Clinical Trials: A New Era Ahead

ALS research is transforming rapidly! From isolated studies to global networks, trials now boost patient access, speed up data collection, and cut timelines. Key shifts: multicenter collaborations reaching more people and adaptive designs for efficiency. Biomarkers like neurofilament light chain are game-changers—detecting changes early, as seen in tofersen’s approval. They’re integrated into trials…

Byneuroots.coDecember 2, 20250Comments

Lifestyle & Health Science & Research

Targeting Aging Pathways with GLP-1 Analogs: From Metabolic Disorders to Healthspan Extension

During the August convening of the Aging Research and Drug Discovery conference in Copenhagen, representatives from Novo Nordisk and Eli Lilly captivated attendees by positing that glucagon-like peptide-1 receptor agonists (GLP-1RAs)—widely recognized for their efficacy in managing obesity and type 2 diabetes—may represent the inaugural class of longevity therapeutics. In addition to their exceptional performance…

Byneuroots.coNovember 30, 20250Comments

MND

Assessment of Residual Plasmid DNA and SV40 Promoter-Enhancer Elements in modRNA-Based COVID-19 Vaccines from Pfizer-BioNTech and Moderna Sourced in Ontario, Canada

David J. Speicher and colleagues. Autoimmunity. 2025 Dec;58(1):2551517. doi: 10.1080/08916934.2025.2551517. Epub 2025 Sep 6. Abstract In the development of certain COVID-19 vaccines, variations occurred between the manufacturing processes for drug substances intended for market release and those employed during clinical evaluations. The production of nucleoside-modified messenger RNA (modRNA) for these commercial vaccines involves in vitro…

Byneuroots.coNovember 30, 20250Comments

Advancements in Artificial Intelligence for Variant Pathogenicity Prediction in Genetic Disorders

The human genome harbors numerous subtle sequence variations, termed variants, which influence protein synthesis within cellular processes. Among these, only a minority exert deleterious effects on protein function, thereby contributing to pathological conditions. Identifying such pathogenic variants amidst the abundance of benign alterations represents a longstanding challenge in genomic medicine. Prior methodologies, including genome-wide association…

Byneuroots.coNovember 30, 20250Comments

Science & Research

Advancements in Antimalarial Therapy: Phase III Outcomes for a Novel Ganaplacide-Lumefantrine Combination

Recent Phase III trial data from Novartis have demonstrated the efficacy of GanLum, an innovative antimalarial regimen comprising ganaplacide and lumefantrine, representing the first novel therapeutic approach for malaria in over two decades. The multicenter study encompassed 1,688 participants, including both adults and pediatric populations, across 12 nations in Africa. Key findings revealed parasite clearance…

Byneuroots.coNovember 30, 20250Comments

News & Events

Artificial Intelligence in Enhancing the Predictability of CRISPR-Based Genome Editing

Advancements in artificial intelligence (AI) are increasingly intersecting with genome editing technologies, potentially mitigating the inherent uncertainties associated with CRISPR systems. This integration aims to streamline experimental workflows and improve outcomes in gene therapy development, although empirical validation in diverse contexts remains ongoing. Consider the case of an undergraduate researcher with limited prior experience in…

Byneuroots.coNovember 29, 20250Comments

Clinical Trials News & Events

A Novel Off-the-Shelf mRNA Vaccine Enters Human Trials for Cancer Treatment

A novel mRNA therapeutic vaccine targeting cancer has progressed to clinical evaluation in humans, offering the potential to broaden therapeutic avenues across diverse tumor types through activation of the host’s innate immunity. Investigators from the University of Florida have commenced human testing of a standardized mRNA vaccine designed to engage the innate immune system, bypassing…

Byneuroots.coNovember 29, 20250Comments